1. Home

Latest news

immagine cervello
Two recent studies demonstrate that the Huntington mutation changes its length over time
Preserving the Brain e Huntington
Preserving the Brain: LIRH Foundation joins Fondazione Prada's 'call to action'
logo prilenia
EMA has agreed to evaluate the MAA for pridopidine for the treatment of Huntington's disease
Consiglio direttivo LIRH Umbria
Lega Italiana Ricerca Huntington continues to grow: LIRH Umbria is born!
immagine dna bianca
Update from Skyhawk Therapeutics on the Phase 1 clinical trial with SKY-0515.
LIRH Friuli Venezia Giulia
Today, on Women's Day, the LIRH Friuli Venezia Giulia Association is officially born.
open access pridopidina
Pridopidine for Huntington's disease now available through an expanded access/compassionate use program
Predicting the severity of HD
Predicting the Severity of Imminent Huntington Disease
glut1 malattia huntington bambini
Breakthrough in the study of Huntington's disease: an alteration in the pediatric HD is not present in the adult HD
Comincia in Italia lo studio Pivot-HD
The phase 2A Pivot-HD clinical study for Huntington disease starts today in Italy
proof-hd
The results of the PROOF-HD study in Huntington's disease are not as expected
Giornata Malattie Rare 2023
Rare Disease Day 2023. Doing well is possible. The example of Huntington's disease.
locandina orizzontale
Clinical trials on Huntington Disease. LIRH Annuale Conference: Rome, December 3, 2022
Aggiornamento sperimentazioni Huntington - Agosto 2022
Huntington's disease trials: update on Vibrant-HD (Novartis) and AMT-130 (uniQure).
Una luce viola per l'Huntington
LIRH Foundation sheds a light on Florence for Huntington's disease
Incontro con le famiglie Huntington sarde - 28 Maggio 2022
LIRH Sardegna and LIRH Foundation meet the HD families to talk about research and care
Foto per LIRH Saedegna
Huntington patients at the forefront of the right to care: the LIRH Sardinia Association was born
Giornata Mondiale Malattie Rare 2022
Rare Disease Day 2022: The colors of Huntington Disease
immagine terapia genica
First Patients dosing in European Open-Label AMT-130 Gene Therapy trial for Huntington's
immagine molecole
Oral drugs, the new frontier in fighting the cause of Huntington's disease
bambini - spazio huntington
Huntington's signs in the first months of life described in a recent study
Luci e ombre sul tominersen
Roche announced a phase II study with tominersen. Do we know enough?
Riserva cognitiva
Hobbies help get better, according to a study conducted on people with Huntington's disease.